Navigation Links
Pain reliever shows anti-viral activity against flu
Date:3/21/2013

The over-the-counter anti-inflammatory drug naproxen may also exhibit antiviral activity against influenza A virus, according to a team of French scientists. The finding, the result of a structure-based investigation, is published online ahead of print in the journal Antimicrobial Agents and Chemotherapy.

New influenza vaccines must be developed annually, because the surface proteins they target mutate rapidly, the way cars used to get a whole new look every year. The researchers, led by Anny Slama-Schwok of the Institut National de la Recherche Agronomique, Jouy en Josas, France, found a much more stable, reliable target for anti-influenza activity. The so-called ribonucleoprotein complexes are necessary for replication, and the researchers realized they could target the nucleoprotein, preventing assembly of the complexes. Because of its vital function, the nucleoprotein is highly conserved, making it a good potential target for antiviral drugs.

The nucleoprotein's three dimensional structure, solved in 2006, provided the basis for searching for new drugs that could interfere with its action. The researchers did a virtual screening within the Sigma-Aldrich online catalog of biochemicals. That screening identified Naproxen, better known as the over-the-counter pain reliever Aleve, and as expected, it bound to the nucleoprotein, and impeded RNA binding, says Slama-Schwok. In further testing, it reduced the viral load in cells infected with H1N1 and H3N2 influenza A virus, and in mice it demonstrated a therapeutic index against influenza A that was superior to that of any other anti-inflammatory drug.

Specifically, naproxen blocks the RNA binding groove of the nucleoprotein, preventing formation of the ribonucleoprotein complex, thus taking the vital nucleoproteins out of circulation. The researchers write that naproxen is a lead compound for drug development that could be improved by tweaking the molecule to boost its ability
'/>"/>

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Researchers explore connection between popular pain relievers, bladder cancer
2. Wellesley study shows income inequality a key factor in high US teen births
3. Invasive heart test being dramatically overused, Stanford study shows
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Lung Cancer Screening Might Pay Off, Analysis Shows
6. Nonsurgical Method to Measure Brain Pressure Shows Promise
7. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
8. Study Shows New Option for Kids With Tough-to-Treat Leukemia
9. Politics May Get in the Way of Empathy, Research Shows
10. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
11. Experimental Pill for Multiple Sclerosis Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... OH (PRWEB) September 30, 2014 ... blades sporting the iconic pink ribbon in support of ... a popular month for businesses and non-profits to “go ... worthwhile cause. , AutoTex PINK is a woman-owned company ... wipers. They are committed to partnering with their ...
(Date:9/30/2014)... 30, 2014 Teeth replacement and restoration ... Institute in Oxnard and Thousand Oaks, Calif., is in ... to provide training on full mouth rehabilitation. , “Full ... implants, providing cosmetic dentistry, correcting bite issues, and resolving ... Dr. Jivraj, who has traveled to India to speak ...
(Date:9/30/2014)... 30, 2014 Loffler Companies, an ... technology and services was recognized by BEI as ... (FCE) in 2013. This prestigious rating means that ... time and for an extended period following, optimizing ... 20 years BEI Services has been the trusted ...
(Date:9/30/2014)... In honor of National Breast Cancer Awareness Month ... battles, Incredible Veins, Body & Skin is offering survivors ... , “For cancer patients who receive radiation treatment, ... their skin to accurately aim the radiation on the ... they decide to have their tattoo removed as the ...
(Date:9/30/2014)... 2014 Julie Kuriakose, MD; ... , will discuss how restaurants can become more allergy-friendly ... dietary restrictions at the 2014 Allergy Eats Food ... October 21 in New York City. , “I’m extremely ... to such an engaged industry audience. As food allergies ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... This strategy beat out either therapy alone, researchers found ... combination of cognitive behavior therapy plus antidepressant drugs is ... thoughts and behavior in depressed teens, new research shows. ... October issue of the journal Archives of General ...
... Health Inc. (Amex: OPK ),has announced the appointment ... Dr. Goldschmidt is the Senior Vice President for Medical,Affairs ... Miller School of,Medicine. Dr. Goldschmidt formerly served as Chairman ... "We are delighted to welcome an exceptional healthcare ...
... Cottage Hospital,which has served thousands of patients from ... 85 years, has rejoined the Henry Ford,Health System. ... Health,System. In 1998, Cottage became part of the Bon ... part of the joint venture,Henry Ford Health System owned ...
... Summit speakers Kenneth,Thorpe, Ph.D. of Partnership to Fight ... on Health, WASHINGTON, Oct. 1 Overhauling ... candidates, but one top,expert believes any serious proposal ... PhD., helped launch the Partnership to,Fight Chronic Disease ...
... 1 Crdentia Corp. (OTC Bulletin,Board: CRDT), a ... posted an exclusive interview on their website with,Michael ... In the interview, Mr. Yao describes how Crdentia,s ... facility contracts and 1,000 travel nurse,needs nationwide. He ...
... that typically fight bacteria, study finds , MONDAY, Oct. ... urban air pollution, shuts down early immune responses in ... vulnerable to bacteria and other foreign invaders, research shows. ... with increased cardiovascular and pulmonary hospitalizations and deaths, but ...
Cached Medicine News:Health News:Drug Plus Psychotherapy Best Treatment for Depressed Teens 2Health News:OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors 2Health News:OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors 3Health News:Grosse Pointe's Cottage Hospital Joins Henry Ford Health System 2Health News:Grosse Pointe's Cottage Hospital Joins Henry Ford Health System 3Health News:URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum 2Health News:URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum 3Health News:Crdentia's National Director of Travel Services Provides an Exclusive Interview on the Growth of Crdentia's Travel Nurse Division 2
(Date:9/30/2014)... 2014 Investor-Edge has initiated coverage ... IMMU ), Aeterna Zentaris Inc. (NASDAQ: AEZS ... Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences ... can be accessed at: http://investor-edge.com/register . ... at 4,505.85, down 0.14%, the Dow Jones Industrial Average ...
(Date:9/30/2014)... , Sept. 30, 2014 It is evident from ... market is not performing upto expectations due to the lack ... asscoaited with the intake of omega-3 fatty acids. Among omega-3 ... the fish oil, attributed to the large vegetarian population in ... omega-3 polyunsaturated fatty acid (PUFAs) ingredients is in growth stage ...
(Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
Breaking Medicine Technology:Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5
... 2007 - Corgenix Medical,Corporation (OTC BB: CONX) ... data demonstrating a significant correlation,between serum levels ... disease. The data was presented at,the XXIst ... and,Hemostasis (ISTH) in Geneva, Switzerland., Data released ...
... of rHuPH20 with Humira Estimated to ... from 64% to 100%,-, SAN DIEGO, ... Inc. , a biopharmaceutical company developing ... that,final results of the Enhanze(TM) Technology ...
Cached Medicine Technology:Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: